InfuSystem Holdings, Inc. (INFU) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INFU SEC filings page.
InfuSystem Holdings, Inc. (INFU) reported $143.3M in revenue over the twelve months to Jun 30, 2026, up 2.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
InfuSystem's recent growth is becoming more profitable and cash-generative while a shrinking debt load supports a more self-funded balance sheet.
From FY2023 to FY2025, revenue rose from$125.8M to$143.4M while gross margin expanded from50.2% to56.0% , indicating improved economics beyond simple sales growth. Over the same span, operating margin increased from3.3% to8.3% , showing that more of the added gross profit reached operating earnings rather than being absorbed by overhead.
In FY2025, operating cash flow of
The balance sheet became less debt-dependent: long-term debt fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of InfuSystem Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
InfuSystem Holdings, Inc. has an operating margin of 8.3%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 54/100, indicating healthy but not exceptional operating efficiency. This is up from 5.1% the prior year.
InfuSystem Holdings, Inc.'s revenue grew 6.4% year-over-year to $143.4M, a solid pace of expansion. This earns a growth score of 56/100.
InfuSystem Holdings, Inc. has a moderate D/E ratio of 0.34. This balance of debt and equity financing earns a leverage score of 55/100.
InfuSystem Holdings, Inc.'s current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 53/100. The company can meet its near-term obligations, though with limited headroom.
InfuSystem Holdings, Inc. converts 16.6% of revenue into free cash flow ($23.8M). This strong cash generation earns a score of 76/100.
InfuSystem Holdings, Inc.'s ROE of 11.6% shows moderate profitability relative to equity, earning a score of 62/100. This is up from 4.1% the prior year.
InfuSystem Holdings, Inc. scores 4.91, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($270.1M) relative to total liabilities ($43.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
InfuSystem Holdings, Inc. passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, InfuSystem Holdings, Inc. generates $3.68 in operating cash flow ($24.4M OCF vs $6.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
InfuSystem Holdings, Inc. earns $9.18 in operating income for every $1 of interest expense ($11.9M vs $1.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
InfuSystem Holdings, Inc. generated $36.9M in revenue in Q2 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 9.6%.
InfuSystem Holdings, Inc.'s EBITDA was $7.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.9% from the same quarter a year earlier. Against the prior quarter it is up 51.3%.
InfuSystem Holdings, Inc. reported $3.2M in net income in Q2 2026. This represents an increase of 24.3% from the same quarter a year earlier. Against the prior quarter it is up 217.7%.
InfuSystem Holdings, Inc. earned $0.15 per diluted share (EPS) in Q2 2026. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 200.0%.
Cash & Balance Sheet
InfuSystem Holdings, Inc. generated $6.7M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 722.4%.
InfuSystem Holdings, Inc. held $964K in cash against $20.4M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
InfuSystem Holdings, Inc.'s gross margin was 58.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.
InfuSystem Holdings, Inc.'s operating margin was 11.2% in Q2 2026, reflecting core business profitability. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.5 percentage points.
InfuSystem Holdings, Inc.'s net profit margin was 8.8% in Q2 2026, showing the share of revenue converted to profit. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.
InfuSystem Holdings, Inc.'s ROE was 5.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.
Capital Allocation
InfuSystem Holdings, Inc. spent $3.5M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 338.7%.
InfuSystem Holdings, Inc. invested $91K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 58.1% from the same quarter a year earlier. Against the prior quarter it is down 42.0%.
Not reported for Q2 2026.
INFU Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.9M+2.6% | $33.7M-3.0% | $36.2M+7.0% | $36.5M+3.3% | $36.0M+6.8% | $34.7M+8.5% | $33.8M+6.5% | $35.3M+10.7% |
| Cost of Revenue | $15.5M-3.8% | $14.0M-9.9% | $15.8M+1.0% | $15.7M-3.7% | $16.1M-5.3% | $15.5M+0.2% | $15.6M+3.8% | $16.3M-0.1% |
| Gross Profit | $21.4M+7.7% | $19.7M+2.7% | $20.4M+12.2% | $20.8M+9.3% | $19.9M+19.2% | $19.2M+16.3% | $18.2M+9.0% | $19.0M+22.0% |
| SG&A Expenses | $14.1M+7.2% | $14.8M-3.3% | $14.1M+6.5% | $14.4M+12.9% | $13.1M+14.1% | $15.3M+11.8% | $13.2M+14.9% | $12.8M+16.8% |
| Operating Income | $4.2M+9.9% | $1.6M+157.3% | $3.7M+42.0% | $3.8M+16.7% | $3.8M+103.6% | $618K+173.1% | $2.6M+109.3% | $3.3M+92.4% |
| EBITDA | $7.3M+2.9% | $4.8M+23.0% | $7.1M+17.0% | $7.1M+10.7% | $7.1M+45.6% | $3.9M+91.6% | $6.0M+37.4% | $6.4M+34.5% |
| Interest Expense | $255K-31.6% | $255K-24.1% | $260K-28.0% | $330K-30.7% | $373K-22.9% | $336K-26.3% | $361K-28.2% | $476K-15.5% |
| Income Tax | $640K-24.4% | $400K-23.1% | $1.5M+9.8% | $1.2M+19.4% | $847K+43.3% | $520K+379.6% | $1.3M+103.2% | $978K+126.9% |
| Net Income | $3.2M+24.3% | $1.0M+480.9% | $2.0M+118.2% | $2.3M+25.0% | $2.6M+262.5% | -$267K+76.0% | $933K+1195.8% | $1.8M+162.3% |
| EPS (Basic) | $0.16+33.3% | $0.05+600.0% | $0.10+150.0% | $0.11+37.5% | $0.12+300.0% | -$0.01+80.0% | $0.04 | $0.08+166.7% |
| EPS (Diluted) | $0.15+25.0% | $0.05+600.0% | $0.09+125.0% | $0.11+37.5% | $0.12+300.0% | -$0.01+80.0% | $0.04 | $0.08+166.7% |
| Diluted Shares (Avg) | 21M-0.6% | 21M-1.1% | N/A | 21M-3.3% | 21M-3.0% | 21M-0.5% | N/A | 22M-0.3% |
Not reported in any period shown, so not listed: R&D Expenses.
INFU Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $97.7M-3.1% | $98.7M-5.4% | $100.6M-2.9% | $98.9M-6.1% | $100.8M-7.1% | $104.3M-0.5% | $103.6M+0.7% | $105.3M+3.2% |
| Current Assets | $38.3M+10.0% | $36.7M+3.8% | $36.3M+13.0% | $35.6M+5.8% | $34.8M+5.7% | $35.3M+8.8% | $32.2M+5.0% | $33.6M+13.1% |
| Cash & Equivalents | $964K+33.9% | $2.1M+39.8% | $3.2M+504.6% | $955K+151.3% | $720K+393.2% | $1.5M+83.2% | $527K+128.1% | $380K+136.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $5.5M-2.6% | $5.8M-4.3% | $5.4M-17.4% | $5.6M-16.6% | $5.7M-17.1% | $6.1M-2.5% | $6.5M+2.0% | $6.7M+10.0% |
| Accounts Receivable | $27.2M+11.1% | $24.0M+0.4% | $22.9M+8.0% | $24.3M+6.8% | $24.5M+14.8% | $23.9M+16.3% | $21.2M+6.9% | $22.8M+17.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% | $3.7M0.0% |
| Total Liabilities | $38.6M-16.8% | $39.9M-18.8% | $43.2M-6.2% | $43.4M-12.8% | $46.3M-15.9% | $49.1M-6.5% | $46.1M-8.9% | $49.8M-1.6% |
| Current Liabilities | $15.3M-3.5% | $17.1M+7.3% | $20.2M+14.3% | $18.7M+10.5% | $15.9M-0.1% | $16.0M-7.8% | $17.7M+12.4% | $16.9M+18.6% |
| Non-Current Liabilities | $23.3M-23.6% | $22.8M-31.4% | $23.1M-18.9% | $24.7M-24.8% | $30.5M-22.2% | $33.2M-5.9% | $28.4M-18.6% | $32.9M-9.6% |
| Long-Term Debt | $20.4M-22.5% | $19.6M-31.6% | $19.6M-17.8% | $20.9M-25.2% | $26.3M-22.9% | $28.7M-4.1% | $23.9M-18.0% | $28.0M-14.3% |
| Total Equity | $59.1M+8.5% | $58.7M+6.5% | $57.3M-0.4% | $55.5M-0.1% | $54.5M+2.0% | $55.1M+5.5% | $57.5M+10.0% | $55.5M+7.9% |
| Retained Earnings | -$60.8M+1.2% | -$60.5M+0.1% | -$60.7M-5.6% | -$61.4M-5.6% | -$61.5M-3.7% | -$60.6M-1.5% | -$57.5M+2.0% | -$58.2M+0.9% |
INFU Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.8M-3.3% | $970K-45.5% | $7.1M-10.2% | $8.5M-13.7% | $7.0M+203.6% | $1.8M+372.1% | $7.9M+70.3% | $9.8M+130.8% |
| Depreciation & Amortization | $3.2M-5.0% | $3.3M-2.0% | $3.3M-2.1% | $3.3M+4.4% | $3.3M+10.2% | $3.3M+14.5% | $3.4M+8.8% | $3.1M+2.5% |
| Stock-Based Compensation | N/A | $1.2M+11.3% | N/A | N/A | N/A | $1.1M+4.8% | N/A | N/A |
| Capital Expenditures | $91K-58.1% | $157K+19.8% | $133K-74.9% | $79K+83.7% | $217K-35.6% | $131K-28.0% | $530K+29.9% | $43K-64.8% |
| Free Cash Flow | $6.7M-1.6% | $813K-50.7% | $7.0M-5.5% | $8.4M-14.1% | $6.8M+244.4% | $1.6M+745.6% | $7.4M+74.1% | $9.8M+136.6% |
| Investing Cash Flow | -$4.5M-168.4% | -$1.3M+52.6% | -$2.2M+32.9% | -$252K+91.2% | -$1.7M+74.8% | -$2.7M-536.6% | -$3.3M-213.1% | -$2.9M-852.0% |
| Financing Cash Flow | -$3.4M+44.4% | -$790K-142.5% | -$2.7M+40.1% | -$8.0M-18.6% | -$6.1M-264.6% | $1.9M+194.3% | -$4.5M-27.4% | -$6.8M-71.5% |
| Share Buybacks | $3.5M+1.4% | $809K-72.1% | $1.3M+556.3% | $2.2M+210.6% | $3.5M+1136.7% | $2.9M | $199K | $698K |
Not reported in any period shown, so not listed: Dividends Paid.
INFU Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.0%+2.8pp | 58.4%+3.2pp | 56.4%+2.6pp | 57.1%+3.1pp | 55.2%+5.7pp | 55.2%+3.7pp | 53.8%+1.2pp | 53.9%+5.0pp |
| Operating Margin | 11.2%+0.8pp | 4.7%+2.9pp | 10.3%+2.5pp | 10.4%+1.2pp | 10.5%+5.0pp | 1.8%+4.4pp | 7.7%+3.8pp | 9.2%+3.9pp |
| Net Margin | 8.8%+1.5pp | 3.0%+3.8pp | 5.6%+2.9pp | 6.2%+1.1pp | 7.2%+5.1pp | -0.8%+2.7pp | 2.8%+2.5pp | 5.1%+3.0pp |
| Return on Equity | 5.5%+0.7pp | 1.7%+2.2pp | 3.5%+1.9pp | 4.1%+0.8pp | 4.8%+3.4pp | -0.5%+1.7pp | 1.6%+1.5pp | 3.3%+1.9pp |
| Return on Assets | 3.3%+0.7pp | 1.0%+1.3pp | 2.0%+1.1pp | 2.3%+0.6pp | 2.6%+1.9pp | -0.3%+0.8pp | 0.9%+0.8pp | 1.7%+1.0pp |
| Current Ratio | 2.50+0.3x | 2.14-0.1x | 1.800.0x | 1.90-0.1x | 2.19+0.1x | 2.21+0.3x | 1.82-0.1x | 1.98-0.1x |
| Debt-to-Equity | 0.35-0.1x | 0.33-0.2x | 0.34-0.1x | 0.38-0.1x | 0.48-0.2x | 0.52-0.1x | 0.41-0.1x | 0.50-0.1x |
| Asset Turnover | 0.380.0x | 0.340.0x | 0.360.0x | 0.370.0x | 0.360.0x | 0.330.0x | 0.330.0x | 0.340.0x |
| FCF Margin | 18.1%-0.8pp | 2.4%-2.3pp | 19.3%-2.6pp | 23.1%-4.7pp | 18.9%+13.0pp | 4.8%+4.1pp | 21.9%+8.5pp | 27.7%+14.8pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| InfuSystem Holdings, Inc. INFU | FY2025 | $143.4M | $6.6M | 4.6% | $270.1M | 59/100 |
| Utah Medical Products Inc UTMD | FY2025 | $38.5M | $11.3M | 29.3% | $236.6M | 78/100 |
| KORU Medical Systems, Inc. KRMD | FY2025 | $41.1M | -$2.6M | -6.4% | $136.7M | 66/100 |
| OraSure Technologies Inc OSUR | FY2025 | $115.0M | -$68.7M | -59.8% | $269.0M | 48/100 |
| Sharps Technology Inc. STSS | FY2025 | $204K | -$282.5M | N/A | $77.9M | — |
Where InfuSystem Holdings, Inc. Ranks
Frequently Asked Questions
What is InfuSystem Holdings, Inc.'s annual revenue?
InfuSystem Holdings, Inc. (INFU) reported $143.4M in total revenue for fiscal year 2025. This represents a 6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is InfuSystem Holdings, Inc.'s revenue growing?
InfuSystem Holdings, Inc. (INFU) revenue grew by 6.4% year-over-year, from $134.9M to $143.4M in fiscal year 2025.
Is InfuSystem Holdings, Inc. profitable?
Yes, InfuSystem Holdings, Inc. (INFU) reported a net income of $6.6M in fiscal year 2025, with a net profit margin of 4.6%.
What is InfuSystem Holdings, Inc.'s EBITDA?
InfuSystem Holdings, Inc. (INFU) had EBITDA of $25.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does InfuSystem Holdings, Inc. have?
As of fiscal year 2025, InfuSystem Holdings, Inc. (INFU) had $3.2M in cash and equivalents against $19.6M in long-term debt.
What is InfuSystem Holdings, Inc.'s gross margin?
InfuSystem Holdings, Inc. (INFU) had a gross margin of 56.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is InfuSystem Holdings, Inc.'s operating margin?
InfuSystem Holdings, Inc. (INFU) had an operating margin of 8.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is InfuSystem Holdings, Inc.'s net profit margin?
InfuSystem Holdings, Inc. (INFU) had a net profit margin of 4.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is InfuSystem Holdings, Inc.'s return on equity (ROE)?
InfuSystem Holdings, Inc. (INFU) has a return on equity of 11.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is InfuSystem Holdings, Inc.'s free cash flow?
InfuSystem Holdings, Inc. (INFU) generated $23.8M in free cash flow during fiscal year 2025. This represents a 23.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is InfuSystem Holdings, Inc.'s operating cash flow?
InfuSystem Holdings, Inc. (INFU) generated $24.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are InfuSystem Holdings, Inc.'s total assets?
InfuSystem Holdings, Inc. (INFU) had $100.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are InfuSystem Holdings, Inc.'s capital expenditures?
InfuSystem Holdings, Inc. (INFU) invested $560K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is InfuSystem Holdings, Inc.'s current ratio?
InfuSystem Holdings, Inc. (INFU) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.
What is InfuSystem Holdings, Inc.'s debt-to-equity ratio?
InfuSystem Holdings, Inc. (INFU) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is InfuSystem Holdings, Inc.'s return on assets (ROA)?
InfuSystem Holdings, Inc. (INFU) had a return on assets of 6.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is InfuSystem Holdings, Inc.'s P/E ratio?
InfuSystem Holdings, Inc. (INFU) trades at 31.6x earnings, its market capitalization divided by net income of $8.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $270.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is InfuSystem Holdings, Inc.'s price-to-sales ratio?
InfuSystem Holdings, Inc. (INFU) trades at 1.9x sales, its market capitalization divided by revenue of $143.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $270.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is InfuSystem Holdings, Inc.'s Altman Z-Score?
InfuSystem Holdings, Inc. (INFU) has an Altman Z-Score of 4.91, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is InfuSystem Holdings, Inc.'s Piotroski F-Score?
InfuSystem Holdings, Inc. (INFU) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are InfuSystem Holdings, Inc.'s earnings high quality?
InfuSystem Holdings, Inc. (INFU) has an earnings quality ratio of 3.68x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can InfuSystem Holdings, Inc. cover its interest payments?
InfuSystem Holdings, Inc. (INFU) has an interest coverage ratio of 9.18x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is InfuSystem Holdings, Inc.?
InfuSystem Holdings, Inc. (INFU) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.